Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma Clinical Trial

Official title:

Phase Ib Clinical Study Evaluating the Efficacy and Safety of TQB2223 Injection Combined With Penpulimab Injection in the Treatment of Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06320080
• Other study ID #: TQB2223-AK105-Ib-01
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: April 2024
• Est. completion date: October 2025

Study information

• Verified date: March 2024
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Shanzhi Gu, Master
• Phone: 13574865998
• Email: 105575191[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. This is a phase Ib study aimed at evaluating the safety, tolerability, and immunogenicity characteristics of TQB2223 injection combined with AK105 injection in the treatment of advanced hepatocellular carcinoma.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 34
• Est. completion date: October 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 18 to 75 years old, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy =3 months;

• Hepatocellular carcinoma (HCC) patients confirmed by pathological histology or cytology examination or meeting the clinical diagnostic criteria for hepatocellular carcinoma according to the American Association for the Study of Liver Diseases (AASLD) or the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2022 edition);

• Have not received any immunotherapy for advanced HCC previously;

• Subjects with a China liver cancer staging (CNLC) of stage III [or Barcelona clinical staging of liver cancer (BCLC) of stage C], or CNLC-II (BCLC-B) subjects who are not suitable for local treatment (such as hepatic artery chemotherapy and embolization) and surgical treatment, or cannot benefit from local treatment and surgical treatment as determined by the investigators;

• Child Pugh liver function grading: Grade A or B (= 7 points)

• Subjects with advanced malignant tumors who failed standard treatment or lacked effective treatment;

• The main organs function well;

• Male or female patient had no plans to become pregnant and agree to voluntarily take effective contraceptive measures during the study to at least 6 months after the last dose of study drug.

Exclusion Criteria:

• Concurrent secondary malignancy or other malignancy with no evidence of disease within 5 years prior to the first dose;

• Within 28 days prior to the first dose, received significant surgical treatment, or with obvious traumatic injury or long-term unhealed wound or fracture;

• Patients who experienced any bleeding or bleeding events = CTC AE level 3 within 4 weeks prior to the first dose; Individuals who have experienced arterial/venous thrombosis events within 6 months prior to the first dose, such as cerebrovascular accidents, deep vein thrombosis, and pulmonary embolism; Low molecular weight heparin treatment is allowed, and antiplatelet drugs are prohibited throughout the entire study period;

• A history of gastrointestinal bleeding such as active gastric and duodenal ulcers, persistent positive fecal occult blood, and ulcerative colitis within 6 months prior to the first dose; Or other conditions determined by investigators that may cause gastrointestinal bleeding or perforation;

• Patients with portal hypertension and at high risk of bleeding considered by the investigators, or have been confirmed by gastroscopy to have red signs or severe esophageal and gastric varicose veins.

• Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;

• Individuals who have previously received or are preparing to undergo allogeneic bone marrow transplantation or solid organ transplantation within 6 months;

• History of hepatic encephalopathy;

• History of uncontrolled intercurrent illness;

• Participants who have participated in other clinical trials of anti-tumor drugs and used other investigational anti-tumor drugs within 4 weeks prior to the first dose;

• Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.

Related Conditions & MeSH terms

• Advanced Hepatocellular Carcinoma
• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• TQB2223 injection
TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.
• Penpulimab Injection
Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.

Locations

Country	Name	City	State
China	Hunan Provincial Tumor Hospital	Changsha	Hunan
China	Affiliated Cancer Hospital of Harbin Medical University	Harbin	Heilongjiang
China	Hubei Provincial Tumor Hospital	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	The percentage of subjects with Complete Response (CR) or partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 and Immune-Modified Response Evaluation Criteria In Solid Tumors (iRECIST).	From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks.
Primary	Progression-free survival (PFS)	The time from the first dose of TQB2223 to the first occurrence of disease progression or death from any cause.	From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks
Secondary	Overall survival (OS)	The time from the first treatment to death from any cause.	From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks
Secondary	Disease control rate (DCR)	The proportion of subjects with Complete response (CR), Partial response (PR), or Stable Disease (SD).	From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks
Secondary	Duration of Response (DOR)	The time from first documented response to documented disease progression or death.	From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks
Secondary	Number of patients with adverse events (AEs) and/or serious adverse events (SAEs)	Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0	From the time of informed consent to 28 days after the last dose
Secondary	Immunogenicity	The occurence of Anti-drug antibody (ADA) after administration	within 1 hour before dose in the 1st, 2nd, 4th, and 8th cycle. 30 and 90 days after the last dose. 21 days as a treatment cycle.